By Akshat Jain MD, MPH Hematology Oncology and Cellular Therapy Faculty Department of Pediatrics & Clinical Medicine Loma Linda University School of Medicine Loma Linda University Children’s Hospital Assistant Professor of Public
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam Roy & Shipra Gandhi Roswell Park Comprehensive Cancer Center The approved
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic Nonsquamous NSCLC Key Points: The KEYNOTE-789 trial did not
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Hodgkin’s lymphoma (HL) has had an exciting and interesting recent history with the introduction of brentuximab (BV) +AVD (Adriamycin, vinblastine,